Blog — Early Menobapuse

One of the primary objectives of the Women's Health Initiative was to see if postmenopausal hormone replacement therapy (HRT) improved long-term risk of coronary heart disease, among other chronic diseases. However, the combined estrogen/progestin (Prempro) arm was halted in 2002, citing that the participants’ risk of cardiovascular disease outweighed any potential benefit of HRT in the prevention of colorectal cancer and bone fracture [1]. The conjugated equine estrogen (CEE)-only arm was also halted in 2004 citing no improvement in heart disease risk but an increased incidence of stroke, and no benefit in terms of fractures, although there was a reduced breast...